Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer ...

The pharmaceutical giant plans to continue offering 23andMe’s DNA testing service and pledged to adopt its privacy practices ...

Regeneron is buying 23andMe for $256M in bankruptcy, gaining access to DNA data from 15 million users to aid drug research.

The acquisition comes two months after the genetic testing company filed for Chapter 11 bankruptcy protection.

Regeneron Pharmaceuticals has promised to comply with 23andMe's existing privacy polices while also using data to fuel drug ...

Regeneron acquires bankrupt 23andMe for $256M, taking over its DNA database and services while pledging to uphold privacy ...

After acquiring 23andMe, Regeneron Pharmaceuticals has said it will protect user data as it uses DNA data for drug ...

Regeneron Pharmaceuticals is set to acquire substantially all assets of 23andMe for $256 million. The deal is expected to ...

The sale was for $256 million and is expected to be complete by the third quarter of this year, according to a Regeneron news ...

Regeneron Pharmaceuticals will acquire embattled DNA testing company 23andMe in a $256 million court-supervised sale, ...

To acquire 23andMe’s Personal Genome Service, Total Health and Research Services business lines, and its Biobank and ...